Nonpreferred Urinary Antibiotics Prior Authorization
Customize your policy alerts
Sign up for allcareadvantage Policy 133.2 alerts
Get alerted when Policy 133.2 changes without checking for updates manually.
Monitor payer policy activity
Defines prior authorization criteria for covering nonpreferred urinary antibiotic agents (gepotidacin, pivmecillinam, sulopenem etzadroxil-probenecid) for treatment of uncomplicated urinary tract infections; applies to AllCare Advantage members and prescribing providers seeking coverage.
No material clinical or coverage changes in this revision.
Coverage Criteria for Nonpreferred Urinary Antibiotics
inv-01: Initial authorization criteria
Covered when ALL of the following are met:
If any of the above fail, deny or forward to MD for review as specified.
inv-02: Renewal criteria
Renewal requests covered when ALL of the following are met:
If renewal criteria are not met, deny.
Requests for members 18 years of age must include supporting evidence that the medication is appropriate for the patient’s age when the member is under 18. Appropriateness for pediatric use must be documented by one of the following: FDA‑approved labeling, a CMS‑approved compendium, or recognized clinical treatment guidelines that support the agent’s use in that age group. If such supporting labeling or compendia/guideline references are not provided for patients <18, the request will be forwarded for MD review or will not meet criteria.
Use will be considered not meeting criteria (and will be denied) when documentation does not support an uncomplicated urinary tract infection (uUTI), or when neither an Infectious Disease (ID) specialist prescription nor a qualifying urine culture is provided. Specifically, requests lacking: (1) documentation of an uncomplicated UTI diagnosis, (2) an ID prescriber or (3) a urine culture demonstrating the uUTI organism is sensitive to the requested medication plus evidence of resistance or contraindication to preferred uUTI antibiotics, should be denied. Additionally, requests that rely on inpatient initiation but do not document that the medication was started while the member was an inpatient will not meet criteria.
Provider Requirements and Authorization Workflow
Prior authorization required; initial approvals up to one fill
Prior authorization is required for nonpreferred urinary antibiotics. Initial approvals are limited to up to one fill when all initial criteria are met, including age requirements, documentation supporting uncomplicated UTI, and either an Infectious Disease (ID) prescriber or culture-based justification with documented resistance/contraindication to preferred agents; approval may also be granted if the medication was started while the member was an inpatient.
- Initial approvals: up to one fill when criteria met
- Criteria include: age ≥18 (or appropriate for age per FDA/CMS/guidelines if <18), documentation of uncomplicated UTI, and either ID prescriber OR documented culture showing susceptibility plus resistance/contraindication to preferred agents; inpatient-start documentation is an alternative justification.
Document resistance or contraindication when not prescribed by ID
If the prescriber is not an Infectious Disease specialist, the request must include documentation that the infecting organism is resistant to or the patient has a contraindication to preferred antibiotics for uUTI; without this sequencing evidence, approval is not supported.
- Requires documented resistance to preferred uUTI antibiotics OR documentation of contraindication to preferred agents when the prescriber is not an ID specialist.
Provide diagnosis, culture results, susceptibilities, and resistance/contraindication evidence
Submit clinical documentation that supports a diagnosis of uncomplicated urinary tract infection. If approval is sought based on culture-directed therapy, include urine culture results identifying the organism and antibiogram/susceptibility showing sensitivity to the requested medication. Also provide evidence of resistance or contraindication to preferred antibiotics and indicate prescriber specialty and whether the medication was initiated during an inpatient stay when applicable.
- Documentation supporting diagnosis of uncomplicated UTI
- Urine culture with organism identification and susceptibilities when relying on culture-directed rationale
- Evidence of resistance or contraindication to preferred agents if not prescribed by an ID specialist
- Prescriber specialty (ID) or documentation that medication was started as an inpatient.
Conditions that will result in denial if criteria not met
The request will be denied if initial or renewal criteria are not met. Triggers for denial include failure to meet age requirements (or lack of supportive FDA/CMS/guideline evidence for patients <18), absence of documentation of uncomplicated UTI, lack of an ID prescriber or a urine culture demonstrating susceptibility plus resistance/contraindication to preferred agents, and absence of inpatient-start documentation when that is the justification. Renewal requests will be denied if prior criteria were not met, there is no documented clinical response, or there is no documentation supporting extension per FDA labeling/CMS compendia/guidelines.
- Denial triggers for initial requests: age not met without supportive labeling/compendia/guidelines, no documentation of uncomplicated UTI, no ID prescriber and no culture demonstrating susceptibility plus resistance/contraindication, or no inpatient-start documentation when relied upon.
- Denial triggers for renewals: member did not meet initial criteria, no documentation of positive clinical response, or no documentation supporting treatment extension per FDA/CMS/guidelines.
Definitions
Background
Uncomplicated urinary tract infections (uUTIs) are commonly caused by Escherichia coli and other gram‑negative organisms. Newer oral agents included in this policy—pivmecillinam, gepotidacin, and sulopenem etzadroxil‑probenecid—are recognized options for treatment of uUTI when resistance or allergies limit use of preferred agents. Gepotidacin has a novel mechanism of action; however, its use should generally be reserved for situations where culture‑directed therapy or specialist assessment justifies its selection to avoid promoting resistance. These agents are included in the policy as nonpreferred urinary antibiotics requiring prior authorization.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.